Department of Rheumatology and Clinical Immunology, Clinical Hospital Center Rijeka, Tome Strižića 3, 51000, Rijeka, Croatia.
Department of Gynaecology and Obstetrics, Clinical Hospital Center Rijeka, Rijeka, Croatia.
Curr Allergy Asthma Rep. 2022 Oct;22(10):135-140. doi: 10.1007/s11882-022-01040-3. Epub 2022 Aug 31.
Hereditary angioedema (HAE) is a disorder affecting bradykinin regulation presenting as recurrent cutaneous or mucosal swelling. Treatment options include plasma-derived or human-recombinant C1-inhibitor, icatibant, or ecallantide. Due to the lack of knowledge and experience on the topic, the treatment of choice in pregnancy is plasma-derived C1-inhibitor, and reporting any new experience is recommended. This review presents current guidelines for HAE treatment with a focus on pregnancy and reviews all experience with icatibant use during pregnancy.
Our experience of treating a pregnant nC1-INH HAE patient with icatibant is presented, with no adverse effects or abnormalities, to add to the growing knowledge of icatibant use during pregnancy. Considering the limited number of attacks that our patient usually experiences, which continued at more or less the same frequency during pregnancy, we feel icatibant to be a safe choice for on-demand HAE treatment during pregnancy for such cases.
遗传性血管性水肿（HAE）是一种影响缓激肽调节的疾病，表现为反复发作的皮肤或黏膜肿胀。治疗选择包括血浆衍生或人重组 C1 抑制剂、依卡替班或艾卡替班。由于缺乏相关知识和经验，血浆衍生 C1 抑制剂是妊娠期间的首选治疗药物，建议报告任何新的经验。本综述介绍了 HAE 治疗的当前指南，重点关注妊娠，并回顾了妊娠期间使用依卡替班的所有经验。
我们介绍了一例使用依卡替班治疗妊娠期 nC1-INH HAE 患者的经验，无不良反应或异常，这增加了关于妊娠期间使用依卡替班的知识。考虑到我们的患者通常发作次数有限，且在妊娠期间发作频率基本相同，我们认为依卡替班是此类情况下妊娠按需治疗 HAE 的安全选择。
